Xilio Therapeutics (NASDAQ:XLO) just reported results for the fourth quarter of 2023.
- Xilio Therapeutics reported earnings per share of -64 cents. This was above the analyst estimate for EPS of -74 cents.
- The company did not report any revenue for the quarter.